Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

dvanced breast cancer," said Elliott Sigal, M.D., Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb.

Registrational Trials

The FDA reviewed the efficacy and safety of IXEMPRA based on the analysis of two multi-center, multinational trials that included 878 patients and evaluated IXEMPRA either as a monotherapy or in combination with capecitabine in patients with metastatic or locally advanced breast cancer.

(Phase II, Monotherapy Trial: -081) The single-arm Phase II trial evaluated the efficacy and safety of IXEMPRA as a monotherapy. This study enrolled 126 patients with metastatic or locally advanced breast cancer resistant to three prior therapies (an anthracycline, a taxane and capecitabine). Resistance was defined as disease progression while on therapy in the metastatic setting (defined as progression while on treatment or within eight weeks of last dose) or recurrence within six months of the last dose in the adjuvant or neoadjuvant setting (only for anthracycline and taxane). HER2 positive patients must also have progressed during or after discontinuation of trastuzumab. The primary endpoint was objective response rate, which is an assessment of tumor shrinkage in response to treatment. Results determined by an independent radiology review (IRR) showed an objective partial response of 12.4% (95% CI, 6.9-19.9) in 113 response-evaluable patients.

Treatment-related non-hematological adverse events (greater than or equal to 20%) included: peripheral sensory neuropathy 62% (Grade 3/4: 14%), fatigue/asthenia 56% (Grade 3/4: 13%), myalgia/arthralgia 49% (Grade 3/4: 8%), alopecia 48% (Grade 3/4: 0%), nausea 42% (Grade 3/4: 2%), stomatitis/mucositis 29% (Grade 3/4: 6%), vomiting 29% (Grade 3/4: 1%), diarrhea 22% (Grade 3/4: 1%), and musculoskeletal pain 20% (Grade 3/4: 3%). Treatment-related hematological adverse events (greater than or equal to 20%) included: neutropenia (Gr
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... on sophisticated equipment, trained personnel, and detection dogs ... terrorist attacks. A revolutionary new electronic chip with ... job much easier. , The groundbreaking nanotechnology-inspired sensor, ... University ,s School of Chemistry and Center for ... company Tracense, picks up the scent of explosives ...
(Date:7/24/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering.  ... is the in vitro growth of plant or animal ... and biopharmaceutical production. Cell culture is a crucial step ... and cell culture consumables are necessary for the in ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... fast becoming one of the most sought-after spokesmen on behalf ... chief information officers and others will have plenty of prospective ... staff openings. , ,Tim Jump, who will speak at ... in Milwaukee, is a pre-engineering teacher by trade, and ...
... - You may have missed this: Web-software services provider ... anchor tenant in a new 165,000-square-foot building being constructed in ... announcement was little noticed outside of commercial real estate development ... story. It's a major technology success story playing out, and ...
... - Public officials on both sides of the aisle ... Republican and Democratic administrations, but judging by the more ... Joint Committee on Finance , there is a ... division was illustrated this week when Joint Finance, in ...
Cached Biology Technology:Jump starting technology education 2Jump starting technology education 3Corporate venturing can nurture software success 2Corporate venturing can nurture software success 3Corporate venturing can nurture software success 4Corporate venturing can nurture software success 5Corporate venturing can nurture software success 6GOP, Dems split over funding of state technology projects 2GOP, Dems split over funding of state technology projects 3GOP, Dems split over funding of state technology projects 4
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... BOSTONA novel study shows that the age girls reach puberty ... differs depending on which parent contributes the gene. This ... rate of development after birth and details of this study ... Age of the first period, known as menarche, is a ... evidence shows that the onset of menses varies between girls, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Could age of first period influence development of diseases in older women? 2
... earliest known ancestor of modern-day birds took to the ... on their arms and legs, according to new research ... published in the journal Paleobiology, Department of Biological Sciences ... began flying by taking off from the ground while ...
... humble honey bee, researchers at the University of Illinois ... the molecular basis of social behavior in humans. , ... model system for social behavior," said Saurabh (pronounced SAW-rub) ... of the university's Institute for Genomic Biology. Using that ...
... discovered that even a small amount of MDMA, better known ... the first study to look at the neurotoxic effects of ... The findings were presented today at the annual meeting of ... a decrease in blood circulation in some areas of the ...
Cached Biology News:Ancient birds flew on all-fours 2Honey bee genome holds clues to social behavior 2Ecstasy can harm the brains of first-time users 2
...
I-Ab MHC Class II...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
... 60 mm Culture Dishes BD BioCoat Collagen ... with a uniform application of rat tail collagen ... I ,Surface : ECM/attachment factors ... nominal : 60 mm x 15 mm ...
Biology Products: